Get started
Author

Murielle Roussel

Observed names: M Roussel, M. Roussel, Muriel Roussel, Murielle ROUSSEL, ROUSSEL, Murielle, Roussel, M. (M.), Roussel, Murielle
Institutions: Centre National de la Recherche Scientifique, Inserm, Centre Hospitalier Universitaire de Limoges, Contrôle de la Réponse Immune B et Lymphoproliférations, Hôpital Universitaire Dupuytren, Centre Hospitalier Laennec, Université de Limoges
Observed institutions: Centre National de la Recherche Scientifique, Inserm, University of Pavia, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Centre Hospitalier Universitaire de Tours, Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Régional et Universitaire de Nancy, Centre Hospitalier Universitaire de Reims, StromaLab, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Limoges, Hôpital Lariboisière, Hôpital Rangueil, Hôpital Pontchaillou, Institut Claudius Regaud, Contrôle de la Réponse Immune B et Lymphoproliférations, Groupe Francophone des Myélodysplasies, Hôpital Purpan, Hôpital Universitaire Dupuytren, Hôpital Saint-Louis, Institut Paoli-Calmettes, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier Laennec, Laboratoire d'hématologie, University College London, University of Turin, Université de Limoges, Institut Curie
ORCID: 0000-0002-4045-9428
Observed ORCID: 0000-0002-4045-9428
OpenAlex ID: A5035919558
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
2017 · Michel Attal, Valerie Lauwers-Cances, et al. · New England Journal of Medicine · 1,251
PDF
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
2012 · Michel Attal, Valerie Lauwers-Cances, et al. · New England Journal of Medicine · 1,158
PDF
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
2019 · Philippe Moreau, Michel Attal, et al. · The Lancet · 967
PDF
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
2008 · Jean-Jacques Kiladjian, Bruno Cassinat, et al. · Blood · 583
PDF
Diagnosis of monoclonal gammopathy of renal significance
2015 · Frank Bridoux, Nelson Leung, et al. · Kidney International · 426
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010 · Hervé Avet-Loiseau, Xavier Leleu, et al. · Journal of Clinical Oncology · 424
PDF
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
2016 · Philippe Moreau, Cyrille Hulin, et al. · Blood · 278
PDF
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
2017 · Thierry Facon, Meletios A. Dimopoulos, et al. · Blood · 271
PDF
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
2014 · Murielle Roussel, Valérie Lauwers-Cances, et al. · Journal of Clinical Oncology · 266
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
2015 · J Laubach, L Garderet, et al. · Leukemia · 258
PDF
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
2013 · Xavier Leleu, Michel Attal, et al. · Blood · 206
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
2021 · Philippe Moreau, Cyrille Hulin, et al. · The Lancet Oncology · 182
PDF
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)
2009 · Murielle Roussel, Philippe Moreau, et al. · Blood · 171
PDF
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
2014 · A. Jaccard, R. L. Comenzo, et al. · Haematologica · 135
PDF
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
2024 · Philippe Moreau, Cyrille Hulin, et al. · The Lancet Oncology · 131
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis
2020 · Murielle Roussel, Giampaolo Merlini, et al. · Blood · 131
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
2010 · Philippe Moreau, Arnaud Jaccard, et al. · Blood · 131
PDF
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)
2015 · Michel Attal, Valerie Lauwers-Cances, et al. · Blood · 125
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
2015 · Marie-Lorraine Chretien, Jill Corre, et al. · Blood · 123
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Xavier Leleu, Cyrille Hulin, et al. · Nature Medicine · 120
PDF
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
2016 · Bruno Royer, Stéphane Minvielle, et al. · Journal of Clinical Oncology · 111
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
2013 · B Hebraud, X Leleu, et al. · Leukemia · 105
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
2015 · Xavier Leleu, Lionel Karlin, et al. · Blood · 103
Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma
2012 · Jill Corre, Elodie Labat, et al. · Cancer Research · 103
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
2015 · Benjamin Hebraud, Florence Magrangeas, et al. · Blood · 97
Works count: 290
Citation count: 10,570
H-index: 44
I10-index: 98
Year
Topic
Type